甲状腺微小乳头状癌的形态学和免疫组织化学研(3)
2015-01-20 01:42
导读：[7] Rapheal SJ, Mckeown-Eyssen G, Asa SL. High-molecular-weight cytokeratin and cytokeratin19 in the diagnosis of thyroid tumor[J]. Mod Pathol, 1994,7（3）:295-301. [8] 何春年，Lili He，Jin QCH，
[7] Rapheal SJ, Mckeown-Eyssen G, Asa SL. High-molecular-weight cytokeratin and cytokeratin19 in the diagnosis of thyroid tumor[J]. Mod Pathol, 1994,7（3）:295-301.
[8] 何春年，Lili He，Jin QCH，等. 甲状腺乳头状癌诊断与鉴别的可靠标记物[J].临床与实验病理学杂志，2007，23（6）：694-698.
[9] 滕晓东，王丽君，姚洪田，等. 细胞角蛋白19、galectin-3、HBME-1在甲状腺病变上的表达及鉴别诊断意义[J].中华病理学杂志,2004，33（3）：212-216.
[10] Schelfhout LJ, Van Muijen GN, Fleuren GJ. Expression of keratin 19 distinguishes papillary thyroid carcinoma from follicular carcinomas and follicular thyroid adenoma[J]. Am J Clin Pathol, 1989, 92（5）:654-658.
[11] Coli A, Bigotti G, Zucchetti F, et al. Galectin-3, a marker of well differentiated thyroid carcinoma is expressed in thyroid nodules with cytological atypical[J]. Histopathology, 2002,40（1）:80-87.
[12] Sapio MR, Guerra A, Posca D, et al. Combined analysis of galectin-3 and BRAFV600E improves the accuracy of fine-needle aspiration biopsy with cytological findings suspicious for papillary thyroid carcinoma[J]. Endocrine-Related Cancer, 2007,14（4）:1089-1097.
[13] Van Hoeven KH, Kovatich AJ, Miettinen M, et al. Immunocytochemical evaluation of HBME-1, CA19-9, and CD15 in fine needle aspirates of thyroid nodules[J]. Diagnostic Cytopathol, 1998,18（1）: 93-97.
[14] 王仪，魏霖，陈昕. Galectin-3、CK19和MC在甲状腺良、恶性肿瘤中的表达及意义[J].海峡药学，2007，19（12）：108-110.
[15] Hoos A, Stojadinovic A, Singh B, et al. Clinical significance of molecular expression profiles of Hürthle cell tumors of the thyroid gland analyzed viatissue microarrays[J]. Am J Pathol, 2002，160（1）:175-183.
[16] Demellawy DEl, Nasrb AL, Babaya S. et al. Diagnostic utility of CD56 immunohistochemistry in papillary carcinoma of the thyroid[J]. Pathol Res Practice, 2009,205（5）:303-309.
